Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

Rhea-AI Summary

Celcuity Inc. (CELC) to release financial results for Q4 and full year 2023. Webcast scheduled for March 27, 2024, to discuss results and corporate update.

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-888-886-7786 or 1-416-764-8658. A live webcast presentation can also be accessed using this weblink:
https://viavid.webcasts.com/starthere.jsp?ei=1655995&tp_key=04c7a07803. A replay of the webcast will be available on the Celcuity website following the live event. 

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is currently enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at Celcuity.com. Follow us on LinkedIn and Twitter.

Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123

ICR Westwicke 
Maria Yonkoski, maria.yonkoski@westwicke.com
(203) 682-7167

When will Celcuity Inc. release its financial results for Q4 and full year 2023?

Celcuity Inc. will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024.

What time is the webcast/teleconference scheduled for discussing the financial results?

The webcast/teleconference to discuss the financial results will be held at 4:30 p.m. Eastern Time on the same day, March 27, 2024.

How can domestic callers participate in the teleconference?

Domestic callers can dial 1-888-886-7786 or 1-416-764-8658 to participate in the teleconference.

Where can the live webcast presentation be accessed?

The live webcast presentation can be accessed using the following weblink: https://viavid.webcasts.com/starthere.jsp?ei=1655995&tp_key=04c7a07803.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the Celcuity website following the live event.